Teva Launches Life Effects Website at IAPO 8th Global Patients Congress

USA - English

• USA - English

NORTH WALES, Pa. (PRWEB) May 29, 2018 -- Teva Pharmaceuticals USA, Inc. (NYSE: TEVA) announced the launch of Life Effects (url: lifeeffects.teva), a new patient-centric website, at the International Alliance of Patients' Organizations (IAPO) 8th Global Patients Congress held on May 23-26, 2018, in Miami.

Developed in collaboration with patients, Life Effects consists of articles, videos and podcasts that offer information, insight and inspiration for people living with one or more chronic conditions. It focuses on the impact a chronic condition has on a patient’s day-to-day life.

“Teva touches the lives of millions of people across the globe on a daily basis. Life Effects is another way in which we demonstrate how we are aligning to meet the evolving needs and expectations of chronically ill patients around the country,” said Brendan O’Grady, Teva’s Executive Vice President and Head of North America Commercial.

Teva created Life Effects after speaking to more than 13,500 patients globally. “We learned that while physicians and other healthcare professionals were patients’ go-to experts when it came to diagnosing a condition and exploring treatment options, there wasn’t a central resource that patients could access on a daily basis when it came to living with a chronic condition,” said Iris Beck-Codner, Teva’s Executive Vice President for Global Brand and Corporate Communications. “We decided to tap into the knowledge and experience of patients themselves to help bridge the information gap.”

“When you’re first diagnosed, no one tells you how your illness is going to affect the non-medical aspects of your life,” said René Brooks, a contributor to Life Effects. “My condition has affected my relationships, my career and my social life…and I wish I knew then what I know now.”

By working with a core group of patients on an ongoing basis, the Life Effects team gets a first-hand, credible perspective on what it’s really like to live with a chronic condition. Together, they tell authentic stories, take a patient-centric look at recent thinking, and offer tips and technologies to help make things a little easier.

The Life Effects team also works with Healthline, the fastest-growing consumer health information site, and Panoply, a premium podcast network which is part of The Slate Group. Healthline and Panoply help Teva integrate the authentic voice and credible point of view of the patient with the rigorous editorial focus of the professional journalist.

At launch, Life Effects will target U.S. patients and focus on four conditions: Attention deficit hyperactivity disorder (ADHD), asthma, depression and migraine. The U.S. launch of Life Effects will be followed by a rollout in Europe later in 2018 that will include an expanded list of conditions.

“We are delighted that Teva accepted our invitation to introduce Life Effects at our global congress. It is a natural fit to this year’s theme of ‘Globally Empowered Patients: Building the Momentum,’ and provides a robust platform for having a dialogue around ways pharma companies, patient groups and others can promote partner-centered healthcare,” said Kawaldip Sehmi, Chief Executive Officer of IAPO.

Earlier this year, Teva announced a new brand positioning—Teva is committed to providing innovative and high-quality medicines to enable people around the world to live better days—and a visual identity, including a new logo. The brand unifies Teva’s businesses around the world after decades of acquisitions and incorporates the company’s untold story on how it impacts the lives of millions of people globally every day. In addition to the U.S., Teva has rolled out the new brand in Canada, France, Russia and Argentina over the past year. Launches in additional markets are planned throughout 2018.

“The new brand is integral to making our mission of bringing valuable medicines to patients easier to execute,” said Beck-Codner. “Life Effects underscores our fresh, updated approach to being more than the world’s largest medicine cabinet. It also demonstrates, in a tangible way, how we are evolving our proposition based on consumer and patient insights and putting patients at the heart of what we do each and every day.”

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2017 were $22.4 billion. For more information, visit http://www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

• our generics medicines business, including: that we are substantially more dependent on this business, with its significant attendant risks, following our acquisition of Allergan plc’s worldwide generic pharmaceuticals business; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; price erosion relating to our generic products, both from competing products and increased regulation; delays in launches of new generic products; our ability to take advantage of high-value biosimilar opportunities; efforts of pharmaceutical companies to limit the use of generics including through legislation and regulations; the difficulty and expense of obtaining licenses to proprietary technologies; returns, allowances and chargebacks; and investigations of the calculation of wholesale prices;
• our specialty medicines business, including: competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions and orally-administered alternatives; our ability to achieve expected results from investments in our product pipeline; competition from companies with greater resources and capabilities; and the effectiveness of our patents and other measures to protect our intellectual property rights;
• our substantially increased indebtedness and significantly decreased cash on hand, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, and may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
• our business and operations in general, including: failure to effectively execute the recently announced restructuring plan; uncertainties related to, and failure to achieve, the potential benefits and success of our new senior management team and organizational structure; harm to our pipeline of future products due to the expected review of our R&D programs; our ability to develop and commercialize additional pharmaceutical products; potential additional adverse consequences following our resolution with the U.S. government of our FCPA investigation; compliance with sanctions and other trade control laws; manufacturing or quality control problems, which may damage our reputation for quality production and require costly remediation; interruptions in our supply chain; disruptions of our or third party information technology systems or breaches of our data security; the failure to recruit or retain key personnel; variations in intellectual property laws that may adversely affect our ability to manufacture our products; challenges associated with conducting business globally, including adverse effects of political or economic instability, major hostilities or terrorism; significant sales to a limited number of customers in our U.S. market; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;
• compliance, regulatory and litigation matters, including: costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into sales and marketing practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
• other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2017, including in the section captioned “Risk Factors,” and in our other filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov and http://www.tevapharm.com. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Elizabeth DeLuca, Teva Pharmaceuticals USA, http://www.lifeeffects.teva, +1 484-612-5407, [email protected]